OBJECTIVE - To examine the effects of crossing over from optimized multiple daily injection (MDI) therapy to sensor-augmented pump (SAP) therapy for 6 months, and the effects of 18 months' sustained use of SAP. RESEARCH DESIGN AND METHODS - The 6-month, single-crossover continuation phase of Sensor-Augmented Pump Therapy for A1C Reduction (STAR 3) provided SAP therapy to 420 subjects who completed the 1-year randomized study. The primary outcome was change in A1C in the crossover group. RESULTS - A1C values were initially lower in the continuing-SAP group than in the crossover group (7.4 vs. 8.0%, P<0.001). A1C values remained reduced in the SAP group. After 3months on the SAP system, A1C decreased to 7.6%in the crossover group (P<0.001); this was a significant and sustained decrease among both adults and children (P < 0.05). CONCLUSIONS - Switching from optimized MDI to SAP therapy allowed for rapid and safe A1C reductions. Glycemic benefits of SAP therapy persist for at least 18 months.
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism
- Advanced and Specialized Nursing